P791 Activation of the aryl hydrocarbon receptor after simvastatin and recombinant antagonist of receptors of interleukin-1 treatment in a rat model of inflammatory bowel disease
Kamyshnyi A., Kamyshna V., Kozachuk A.
Zaporozhye State Medical University, Zaporozhye, Ukraine
The pathogenesis of inflammatory bowel disease is complex and multifactorial. Studies have led to the current concept that aryl hydrocarbon receptors have recently emerged as a critical physiological regulator of immune responses affecting both innate and adaptive systems. We studied the possibility of simvastatin and antagonist of receptors of interleukin-1 for pharmacological correction of colitis in rats with a focus on the expression intensity studies of AhR with lymphocytes of colon.
Experiments were carried out on male Wistar rats aged 8 months (body mass 260–285 g). Rats were divided into four experimental groups: group 1 – control; group 2 – rats with oxazolone-induced colitis; group 3 – rats given simvastatin (20 mg/kg, for 5 days, intraperitoneally); group 4 – rats given antagonist of receptors of interleukin-1 (3 mg/kg, for 5 days, subcutaneously). The AhR immunopositive lymphocytes were determined using an indirect immunofluorescence technique with using a monoclonal rat antibody.
We established that development of colitis was not accompanied with the change of amount of AhR+ lymphocytes in immunopositive cells. Drug administration during the development of experimental pathology was accompanied by changes in the expression of AhR on lymphocytes.
Simvastatin and antagonist of receptors of interleukin-1 seemed to be beneficial in oxazolone -induced colitis rat model through modulate AhR expression with lymphocytes of colon.